Acomplia diet drug

 ACOMPLIA - GENERIC ACOMPLIA ( Rimonabant )

Rimonabant (Generic Acomplia) is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges, such as smoking. This is a non-control weightloss solution that in one study, helped people who were overweight drop an average of 20 pounds, and was found to be very useful for patients who suffer from obesity.

Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and
abnormal levels of fat in the blood. Patients with large waist
circumference (102 cm in men and 88 cm in women) will
mostly benefit from taking Acomplia.

H ow does it work?

Acomplia tablets contain the active ingredient rimonabant, which is a type of medicine called a cannabinoid-1 receptor antagonist. It is used to aid weight loss in people who are obese or overweight.

Rimonabant works by blocking receptors called cannabinoid-1 receptors (CB1). These are found in the brain, fat tissue, digestive system, liver and muscles.

The CB1 receptors are part of a system in the body called the endocannabinoid system. This system has only recently been discovered and explored. It is involved in regulating energy balance, sugar and fat metabolism and body weight.

The CB1 receptors found in a particular area of the brain called the mesolimbic system are involved in controlling our intake of highly palatable, sweet or fatty foods. Overactivation of the CB1 receptors is associated with increased appetite, cravings for food and fat build-up.

If you take the diet drug Acomplia, you can keep off lost pounds only if you keep taking it, researchers say.

And those who stay on the drug keep their smaller waist, lower blood-fat levels, and higher good cholesterol levels.

If you don’t cut your calories, Acomplia won’t help you lose weight. But obese and overweight people who do eat less lost an average of 14 pounds if they were able to take Acomplia for one year. That’s 10.5 pounds more than those who ate less and got an inactive placebo pill, reports F. Xavier Pi-Sunyer, MD, professor of medicine at Columbia University and chief of endocrinology at St. Luke’s-Roosevelt Hospital, New York.

“I think it is exciting, because [Acomplia] has a new mechanism of action, and seems as effective [for weight loss] as any drug on the market,” Pi-Sunyer tells WebMD. “[Acomplia] does a reasonable job of modest weight loss.”

The results, first reported in 2004, appear in the Feb. 15 issue of The Journal of the American Medical Association.

The FDA has not yet approved Acomplia, but is expected to act soon. In clinical trials, the drug has helped people lose weight. Obese people seem to have an overactive cannabinoid system. By partially shutting this system down, Acomplia helps people resist the craving for highly palatable food popularly known as ‘the munchies.’

How Rimonabant (Acomplia) can help to lose your weight??

Rimonabant acomplia block the cannabinoid receptors in the brain that reduce appetite. Blocking these receptors by rimonabant, might also help people to controlling food intake and you will start losing your weight by rimonabant. New study published in medical journal The Lancet, confirms the rimonabant acomplia can help in weight loss and reduce the risk factors associated with heart disease.So buy Acomplia for effective weight management.

            More than 1,500 obese people were given a calorie-controlled diet, with either 5mg or 20mg drug of rimonabant acomplia for each day. After one year, two thirds of the participants taking the largest dose had loss at least 5 percent of their initial weight by using rimonabant acomplia.39 percent of people loss more than 10 percent of weight by using Rimonabant acomplia. Patients on the 20mg Rimonabant (acomplia) dose loss on average, 4cm from their waist and risk factors for heart disease including raised cholesterol, insulin resistance and the presence of metabolic syndrome improved.

            Rimonabant is a great weight loss pill for the patient of obesity. Order Rimonabant acomplia, a miracle drug for obesity. Buy rimonabant (acomplia) online and start weight loss from now.

             Rimonabant Acomplia diet pill is the first in a class of a drug called cannabinoid receptor type1 (CB1) Blockers. Rimonabant (acomplia) diet pill helps people to winning the weight loss battle.

What Can a Dieter Expect from Rimonabant in Regards to Weight Loss

            In regards to weight loss, studies conclude that the person who taking Rimonabant Acomplia regularly can aspect significant weight loss results. Around 33% of the people who took Rimonabant (Acomplia) diet pill for two years can lost their weight around 5% to 10% of initial weight. People who taking Acomplia Rimonabant diet pill can control the weight and cholesterol levels. This helps them to reduce the cardiovascular risk.

Rimonabant Acomplia diet pill is useful for the patients of obesity !

Acomplia (rimonabant) is the first medication in a class known as endocannabinoid CB1 receptor antagonists to be approved in the UK. This makes Acomplia a revolutionary way of tackling obesity and it has been prescribed to over 100,000 people in Europe since its launch in June 2006.

Acomplia is a prescription medication so you must complete an online consultation form before you can purchase this medication. Consultations are free and you are under no obligation to make a purchase.

Little is known about the endocannabinoid system as it has only recently been discovered and explored but it is believed to regulate energy consumption and expenditure. The endocannabinoid system comprises (amongst other components) cannabinoids (chemical signals) and CB receptors. The CB1 receptors are located in the brain, certain organs and peripheral tissues such as fat cells. Cannabinoids, naturally occurring chemicals produced by the body, attach themselves to CB1 receptors, at which point a signal is transmitted, indicating to the brain that we should eat something. Studies have demonstrated that the endocannabinoid system tends to be more active in overweight people. In simplistic terms, Acomplia (Rimonabant) prevents the CB1 receptors from working in an overactive way, thereby helping to regulate and normalise the operation of the endocannabinoid system, which should, in turn, allow overweight people to lose weight.

Acomplia (Rimonabant) was tested on 6800 volunteers during the phase 2 and phase 3 clinical trials. The phase 3 trial lasted for two years and was compared with a placebo control group. Both groups were asked to increase their level of physical activity. It was demonstrated that those taking Acomplia lost on average 4 times more weight than those taking the placebo. Most of the weight loss occurred in the first 9 months of treatment but the weight loss was maintained until the end of the two year trial. Acomplia does not work for everyone but just over 50% managed a weight loss of 5% and approximately 27% managed a weight loss of 10% or more of their overall body weight.

The study comprising the phase 3 clinical trial demonstrated that waist circumference was reduced. An expansive waist circumference is thought to be a marker for the visceral fat which has been linked to diabetes and heart disease. It was also demonstrated that patient cholesterol levels were improved beyond that which would normally be expected from weight loss alone after being treated with Acomplia. There is also evidence to suggest that Acomplia (Rimonabant) might be effective in helping people who want to give up smoking although it has not been approved for this purpose. If you are looking for help in giving up smoking, we will happily provide you with a free consultation for a smoking cessation aid. We are only prepared to prescribe Champix as a smoking cessation aid as we believe that this is the safest and most effective treatment currently available.

no doubt you’ve heard the buzz: There’s a drug on the horizon that melts pounds by blocking cravings. The medication, to be called Diet pill Acomplia, will soon be submitted for FDA approval. Here’s the skinny. What makes Acomplia diet pill different from other diet drugs? It works specifically on cravings by shutting off certain receptors in the brain. “pill Acomplia diet decreases the urge to overeat, so you lose weight,” explains Richard L. Atkinson, M.D., president of the American Obesity Association and one of the researchers who has studied the drug. Is it really the …

Vivian Cota leaned on her shopping cart in the diet aisle of a San Jose Walgreens, eyeing the thick, locked plastic case labeled “Alli.”She has tried numerous other boxes on this shelf — the green tea supplements, the 10-day Hoodia diet. And now it’s time for something new.”I’m very interested in this,” said the 65-year-old San Jose woman, unhappy that the drug couldn’t be purchased until Friday. “You reach a plateau, and then you have to try something else.”As Alli, the first FDA-approved diet drug cleared for over-the- counter sale, arrived Friday in drugstores nationwide, doctors and nutritionists were trying to counter that intense consumer interest and a marketing juggernaut with some spin of their own, arguing that the drug’s high cost and limited effectiveness may not be worth its notably unpleasant side effects.

Alli (pronounced “ally”), sold by GlaxoSmithKline, is a half- dose of the prescription drug orlistat. The drug has been marketed in prescription form by Roche Holding AG under the brand name Xenical since 1999, but it never turned out to be a blockbuster.GlaxoSmithKline, however, expects Alli ultimately to rake in at least $1.5billion in annual sales, and the company is expected to spend $150million on marketing the drug in its first year. Television and magazine ads are running. E-tailers Amazon.com and Drugstore.com report that the drug, which has been pre-sold, already is a top seller — even at a cost of $50 to $60 for a month’s supply.

It sounds too good to be true:A pill that helps you lose weight, quit smoking, and reduce the cardiovascular risks for diabetes and heart disease.Sanofi-Aventis SA’s new treatment, Acomplia, also known as rimonabant, has shown promise in a half-dozen clinical trials in curbing the cravings that make people hungry and reach for a cigarette.The experimental drug, which works differently from other weight-loss medicines, could be approved by the Food and Drug Administration as soon as this month. And industry analysts predict it could become the world’s first blockbuster antiobesity treatment, with annual sales of 2 billion to 4 billion euros, or $2.4 billion to $4.8 billion.